A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf
.
Natural Progression of Diabetic Peripheral Neuropathy in the Zenarestat Study Population
2004
Diabetes Care
OBJECTIVE -The aim of this study was to report the baseline and natural progression of diabetic peripheral neuropathy over 12 months in a large mild-to-moderate neuropathy population. RESEARCH DESIGN AND METHODS -Patients from a multicentered trial of zenarestat, an aldose reductase inhibitor, had serial measures of neurologic function, including nerve conduction studies (NCSs), quantitative sensory testing (QST), and clinical neuropathy rating scores at baseline and at 12 months. Baseline
doi:10.2337/diacare.27.5.1153
pmid:15111537
fatcat:2mrq74724feyvos5jtkgpfitxm